Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

Phase 3

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency Identifier: NCT03037931
Recruitment Status: Recruiting
First Posted: 1/31/2017 12:00:00 AM
Last Update Posted: 5/10/2019 12:00:00 AM


Anemia, Iron-Deficiency
Heart Failure


Drug: Placebos / Normal Saline Solution

Detailed Description

This is a double-blind, multicenter, prospective, randomized, placebo-controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) for patients in heart failure with iron deficiency. After an initial screening period of up to 28 days, eligible participants will be stratified by region and randomized in a 1:1 ratio to FCM or placebo for treatment. Study drug administration will occur on Day 0 and Day 7 (±2) as an undiluted slow IV push, with additional study visits planned at 3 month intervals, and additional dosing administered every 6 months as applicable. In a subset of sites, a sub-study will be conducted to characterize serum phosphate levels overtime in participants with heart failure and iron deficiency after dosing with FCM. For all participants, hematology, ferritin, and transferrin saturation (TSAT), with appropriate safety evaluations, to determine additional treatment, will occur at 6 month intervals.

You may be eligible to join if...

1. adult (≥18 years of age) able to provide informed consent.

2. stable heart failure (nyha ii-iv) on maximally-tolerated background therapy (as
determined by the site principle investigator) for at least 2 weeks prior to

3. able and willing to perform a 6mwt at the time of randomization.

4. reduced left ventricular ejection fraction. assessment must be performed at least 12
weeks after major cardiac surgical intervention including coronary artery bypass graft
(cabg), valvular repair/replacement, or cardiac resynchronization therapy (crt) device

a. left ventricular ejection fraction ≤ 40% obtained during the screening visit or
either of the following i. historical value of ejection fraction ≤ 40% within 24
months of screening visit ii. historical value of ejection fraction ≤ 30% within 36
months of screening visit

5. hemoglobin >9.0 g/dl and < 13.5 g/dl (females) or <15.0 g/dl (males) within 28 days of

6. serum ferritin <100 ng/ml or 100 to 300 ng/ml with tsat <20%.patients with screening
ferritin <15 ng/ml must have documentation of an appropriate evaluation, as determined
by the principle investigator, within 3 months of screening and prior to

7. either documented hospitalization for heart failure within 12 months of enrollment or
elavated n-terminal-pro-brain natriuretic peptide (nt-probnp) within 90 days of
randomization. a. for patients in normal sinus rhythm: n-terminal-pro-brain
natriuretic peptide (nt- probnp) > 600 pg/ml (or bnp >200 pg/ml) . b . for patients in
atrial fibrillation: nt-probnp >1000 pg/ml (or bnp >400 pg/ml) .

You may NOT be eligible to join if...

1. known hypersensitivity reaction to any component of fcm.

2. history of acquired iron overload, or the recent receipt (within 3 months) of
erythropoietin stimulating agent, iv iron therapy, or blood transfusion.

3. acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or
stroke within 30 days of enrollment.

4. uncorrected severe aortic stenosis, severe valvular regurgitation, or left ventricular
outflow obstruction requiring intervention.

5. current atrial fibrillation or atrial flutter with a mean ventricular response rate
>100 per minute (at rest).

6. current or planned mechanical circulatory support or heart transplantation.

7. hemodialysis or peritoneal dialysis (current or planned within the next 6 months).

8. documented liver disease, or active hepatitis (i.e. alanine transaminase or aspartate
transaminase >3 times the upper limit of normal range).

9. current or recent (within 3 years) malignancy with exception of basal cell carcinoma
or squamous cell carcinoma of the skin, or cervical intraepithelial neoplasia.

10. active gastrointestinal bleeding.

11. female participant of child-bearing potential who is pregnant, lactating, or not
willing to use adequate contraceptive precautions during the study and for up to 5
days after the last scheduled dose of study medication.

12. inability to return for follow up visits within the necessary windows

13. concurrently in a study with investigational product.

Learn About Clinical Trials


Your Clinical Trial Journey: Understanding the Clinical Trial Landscape

As you embark on your clinical trial journey, you may be asking: What happens before the drug gets tested in humans? What is a clinical trial? How come some clinical trials have few participants and some have hundreds or...

Read More



Clinical Trials Consist of Four Phases: What are they?

Clinical trials is a term that many people have heard, but not enough seem to know about. Conducted to collect data about the efficiency and safety of a potential new treatment option, clinical trials are multi-level processes...

Read More



The Importance of Volunteering in a Clinical Trial

I have always been someone that loves to volunteer and help the local community. I have participated in food drives, given back to the local animal shelter and volunteered at my local ambulance corp. Volunteers are apart of our everyday life, but they seem to be somewhat easily forgotten about. Think about it. You don’t often think about an EMT or volunteer firefighter...

Read More



Amazon, Uber, Yelp...Why Not Clinical Trials?

So you call an Uber, you see your driver has a low rating, do you really want to get in the car or are you now feeling skeptical? Or picture this- you are going on a weekend trip with your friends you haven’t seen in years and you want to pick the best restaurants in the area...

Read More


The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Go to >